News
02-23-2016, 04:12 AM
Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy.
More... (http://www.news-medical.net/news/20160223/Pfizere28099s-IBRANCE-(palbociclib)-now-approved-for-use-in-women-with-HR2b-HER2-metastatic-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20160223/Pfizere28099s-IBRANCE-(palbociclib)-now-approved-for-use-in-women-with-HR2b-HER2-metastatic-breast-cancer.aspx)